Stephen A Adamu, Ed.D, MBA, MS.
Adjunct Faculty Member
Office Hours: By appointment only
About
Stephen A. Adamu, Ed.D., MBA., MS.
I received a Doctor of Education in Organizational Leadership (Ed.D) and a Master degree in Business Administration (MBA) from Pepperdine University. I obtained a Master of Science degree (MS) in Microbiology from Rhode Island University, and a Bachelor of Science degree (BS) in Zoology from Ohio University. Prior to California Lutheran University, I had 16 years of University/Academic experience as an associate research scientist at University of California at Los Angeles in the departments of Infectious Diseases and Ophthalmology. I acquired 11 years of Biotechnology/Biopharmaceutical industry research experience at Amgen Inc. As a senior associate research scientist in Amgen’s pre-clinical drug development, I provided scientific support in discovery research and development of therapeutic compounds.
My research and teaching interests include Corporate Social Responsibility, Business Strategy, Organizational Culture and Innovation, drug development, drug efficacy, and microbial pathogenicity.
Beyond academia, my interests are travelling, working out, and Jazz music.
Education
Stephen A. Adamu, Ed.D., MBA., MS.
EDUCATION:
Ed.D. - Doctor of Education in Organizational Leadership, Pepperdine University Graduate School of
Education and Psychology, Los Angeles, CA May 2017
Dissertation topic – Impact of Corporate Social Responsibility on Financial Performance in
the Pharmaceutical Industry
Comprehensive Exam topic – Maximizing Organizational Potential of a Pharmaceutical
Company: A Strategic Business Initiative to Improve Genmapp.
MBA – Master of Business Administration, Pepperdine University, Malibu, California 2002
MS - Master of Science in Pathogenic Microbiology, University of Rhode Island, Kingston,
Rhode Island 1980
BS – Bachelor of Science in Zoology, Ohio University, Athens, Ohio 1975
Expertise
My expertise and interests include Corporate Social Responsibility, Business Strategy, Organizational Culture and Innovation, drug development, drug efficacy, and microbial pathogenicity.
Publications
Stephen A. Adamu, Ed.D., MBA., MS.
PUBLICATIONS:
Li X, Ominsky MS, Stolina M, Warmington KS, Geng Z, Niu QT, Asuncion FJ, Tan HL, Grisanti M, Dwyer D, Adamu S, Ke HZ, Simonet WS, Kostenuik PJ. Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin. Bone 45(4): 669-76, 2009.
Ominsky MS, Stolina M, Li X, Corbin TJ, Asuncion FJ, Barrero M, Niu QT, Dwyer D, Adamu S, Warmington KS, Grisanti M, Tan HL, Ke HZ, Simonet WS, Kostenuik PJ. One year of transgenic overexpression of osteoprotegerin in rats suppressed bone resorption and increased vertebral bone volume, density, and strength. Journal of Bone & Mineral Research 24(7): 1234-46, 2009.
Yuan YY, Kostenuik PJ, Ominsky MS, Morony S, Adamu S, Simionescu DT, Basalyga DM, Asuncion FJ, Bateman TA. Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease. Osteoporosis International. 19(5): 625-35, 2008.
Kostenuik PJ, Ferrari S, Pierroz D, Bouxsein M, Morony S, Warmington KS, Adamu S, Geng Z, Grisanti M, Shalhoub V, Martin S, Biddlecome G, Shimamoto G, Boone T, Shen V, Lacey D. Infrequent delivery of a long-acting PTH-Fc fusion protein has potent anabolic effects on cortical and cancellous bone. Journal of Bone & Mineral Research 22(10): 1534-47, 2007.
Li J, Sarosi I, Cattley RC, Pretorius J, Asuncion F, Grisanti M, Morony S, Adamu S, Geng Z, Qiu W, Kostenuik P, Lacey DL, Simonet WS, Bolon B, Qian X, Shalhoub V, Ominsky MS, Ke HZ, Li X, Richards WG. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia, Bone 39: 754-766, 2006.
Marina Stolina, Stephen Adamu, Mike Ominsky, Denise Dwyer, Frank Asuncion, Zhaopo Geng, Scot Middleton, Heather Brown, Jim Pretorius, Georg Schett, Brad Bolon, Ulrich Feige, Debra Zack, and Paul J Kostenuik. RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis. J Bone and Mineral Research 20: 1756-1765, 2005.
Sean Morony, Kelly Warmington, Stephen Adamu, Frank Asuncion, Zhaopo Geng, Mario Grisanti, Hong Lin Tan, Casey Capparelli, Charlie Starnes, Bernadette Weimann, Colin R. Dunstan, and Paul J. Kostenuik: The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. Endocrinology 146(8): 3235–3243, 2005.
Bo Abrahamsen, Jacob vB Hjelmborg, Paul Kostenuik, Lis S Stilgren, Kirsten Kyvik, Stephen Adamu, Kim Brixen, Bente L Langdahl. Circulating amounts of osteoprotegerin and RANK ligand: Genetic influence and relationship with BMD assessed in female twins: Heritability of OPG and RANKL in twins. Bone 36: 727– 735, 2005.
F R Byrne, S Morony, K Warmington, Z Geng, H L Brown, S A Flores, M Fiorino, S L Yin, D Hill, V Porkess, D Duryea, J K Pretorius, S Adamu, R Manuokian, D M Danilenko, I Sarosi, D L Lacey, P J Kostenuik, G Senaldi CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin Gut 2005; 54: 78–86.
Charles Capparelli, Sean Morony, Kelly Warmington, Stephen Adamu, David Lacey, Colin R. Dunstan, Brian Stouch, Steven Martin, and Paul. J. Kostenuik. Sustained antiresorptive effects after a single treatment with human recombinant Osteoprotegerin (OPG): A pharmacodynamic and pharmacokinetic analysis in rats. J Bone and Mineral Research 18: 852-858, 2003.
Paul. J. Kostenuik, Casey Capparelli, Sean Morony, Stephen A. Adamu, Grant Shimamoto, Victor Shen, David L. Lacey, and Colin R. Dunstan. OPG and PTH- (1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. Endocrinology 142(10): 4295-4304, 2001.
Giese MJ, Adamu SA, Pitchekian-Halabi H, Ravindranath RMH, Mondino BJ: The effect of Staphylococcus aureus Phage Lysate vaccine on a rabbit model of staphylococcal blepharitis, phlyctenulosis and catarrhal infiltrates. Am. J. Ophthalmol. 122:245-254, 1996.
Ravindranath RMH, Mondino BJ, Adamu SA, Pitchekian-Halabi H, Hasan SA, Glasgow BJ: Immopathological features of Staphylococcus aureus endophthalmitis in the rat. Invest. Ophthalmol. Vis. Sci. 36:2482-2491, 1995.
Giese MJ, Mondino BJ, Glasgow BJ, Sumner H, Adamu SA, Pitchekian-Halabi H, Chou HJ: The complement system and host defense against staphylococcal endophthalmitis. Invest. Ophthalmol. Vis. Sci. 35:1026-1032, 1994.
Milani JK, Verbukh I, Pleyer U, Sumner H, Adamu SA, Pitchekian-Halabi H, Chou HJ, Lee DA, Mondino BJ: Collagen Shields impregnated with gentamicin-dexamethasone as a potential drug delivery device. Am J Opthalmol 116:622-627, 1993.
Pleyer U, Mondino BJ, Adamu SA, Pitchekian-Halabi H, Engstrom RE, Glasgow BJ: Immune response to Staphylococcus epidermidis-induced endophthalmitis in a rabbit model. Invest. Ophthalmol. Vis. Sci. 33:2650-2663, 1992.
Mondino BJ, Adamu SA, Pitchekian-Halabi H: Antibody studies in a rabbit model of the corneal phlyctenulosis and catarrhal infiltrates related to Staphylococcus aureus. Invest. Ophthalmol. Vis. Sci. 32:1854-1863, 1991.
Engstrom RE, Mondino BJ, Glasgow BJ, Pitchekian-Halabi H, Adamu SA: Immune response to Staphylococcus aureus endophthalmitis in a rabbit model. Invest. Ophthalmol. Vis. Sci. 32:1523-1533, 1991.
Mondino BJ, Adamu SA: Ocular immune response to Staphylococcus epidermidis. In: The Cornea: Transactions of the World Congress on the Cornea III. (Ed.) Cavanaugh HD. Raven Press, Ltd. New York, 1988, pp. 431-433.
Mondino BJ, Brawman-Mintzer O, Adamu SA: Corneal antibody levels to ribitol teichoic acid in rabbits immunized with staphylococcal antigens using various routes. Invest. Ophthalmol. Vis. Sci. 28:1553-1558, 1987.
Mondino BJ, Laheji K, Adamu SA: Ocular Immunity to Staphylococcus aureus. Invest. Ophthalmol. Vis. Sci. 28:560-564, 1987.
Stevens P, Young LS, Adamu SA, 1983. Opsonization of various capsular (K) E. coli by the alternative complement pathway. Immunology 50:497-502.
Adamu SA, Sperry JF, 1981. Polymorphonuclear neutrophil chemotaxis induced and inhibited by Bacteroides fragilis. Infect Immune 33:806-810.
ABSTRACTS & PRESENTATIONS:
Ominsky MS, Corbin T, Stolina M, Dwyer D, Li X, Morony S, Warmington KS, Geng Z, Grisanti M, Tan H, Adamu S, Asuncion F, Bolon B, McCabe J, Kostenuik PJ. Serum OPG levels are correlated positively with bone strength and inversely with bone turnover in mature OPG transgenic rats. Calc Tiss Int 78 (S1): OC032, 2006.
Ominsky MS, Corbin TJ, Stolina M, Dwyer D, Li X, Morony S, Warmington KS, Geng Z, Grisanti M, Tan H, Adamu S, Asuncion F, Bolon B, McCabe J, Kostenuik PJ, Bone strength is inversely related to bone turnover in mature transgenic rats overexpressing the RANKL inhibitor OPG, Osteoporosis Intl 17 (S2): OC11 (S9-10), 2006.
Li X, Asuncion F, Ominsky MS, Adamu S, Dwyer D, Stolina M, Tan HL, Grisanti M, Warmington KS, Kostenuik PJ, RANKL Inhibition with OPG preserves bone density and trabecular architecture in ovariectomized rats, J Bone Min Res 21 (S1): SU386, 2006.M.
Stolina, S. Adamu, D. Dwyer, S. Middleton, F. Asuncion, M. Ominsky, G. Schett, U. Feige, P. Kostenuik, D. J. Zack. RANKL inhibition with Osteoprotegerin (OPG) prevents bone loss but does not affect immune status in arthritic rats. J Bone Min Res 20 (Suppl. 1): S257, 2005.
Li X, Capparelli C, Morony S, Adamu S, Asuncion F, Hoffman K, Grisanti M, Tan HL, and Kostenuik PJ. The RANKL inhibitor osteoprotegerin causes rapid and significant increases in bone density in rats co-treated with parathyroid hormone. Bone 36 (Suppl. 2): S299, 2005.
P. J. Kostenuik, K. Warmington, M. Grisanti, S. Morony, Z. Geng, H. L. Tan, C. Christensen, J. Sullivan, H. Nguyen, S. Adamu, F. Asuncion, M. Ominsky, X. Li, J. McCabe. RANKL inhibition with AMG 162, a fully human mAb, causes sustained suppression of bone resorption and increased BMD in knockin mice expressing humanized RANKL. J Bone Min Res 20 (Suppl. 1): SU304, 2005.
Stolina M, Middleton S, Adamu S, Asuncion F, Geng Z, Ominsky M, Zack D, McDormand K and Kostenuik P. 2005 The RANKL inhibitor osteoprotegerin (OPG) prevents focal bone erosions in adjuvant arthritic rats without inducing renal pathology: A comparison with zoledronic acid. EULAR 2005, Ann Rheum Dis 64:441.
Y. Y. Yuan, A. G. Lau, P. J. Kostenuik, S. Morony, S. Adamu, F. Asuncion, T. A. Bateman. Soluble RANKL Has Detrimental Effects on Cortical and Trabecular Bone Volume, Mineralization and Bone Strength in Mice. J Bone Min Res 20 (Suppl. 1): S161-162, 2005.
P. J. Kostenuik, F. Asuncion*, K. Warmington*, S. Morony, H. Tan, M. Grisanti*, S. Adamu. Metabolic Disorders, Amgen, Inc., Thousand Oaks, CA, USA. Coupling of bone resorption and bone formation: A comparison of a RANKL antagonist (OPG) and bisphosphonates in mice. ASBMR 2004 Abstract # M300.
J. Li, I. Sarosi*, S. E. Morony, D. Hill*, Y. Wang*, W. Qiu*, S. Adamu*, M. Grisanti*, K. Hoffmann*, T. Gyuris*, H. Nguyen*, R. Cattley*, P. J. Kostenuik, S. S. Simonet, D. L. Lacey. Amgen Inc., Thousand Oaks, CA, USA. Transgenic Mice Over-Expressing Dkk-1 in Osteoblasts Develop Osteoporosis. ASBMR 2004 Abstract # 1017.
Stolina M, Schett G, Bolon B, Middleton S, Brown H, Zhu L, Adamu S, Asuncion F, Kostenuik P, Feige U, Zack D, Bone loss in inflammatory arthritis is associated with a local and systemic decrease in parameters of bone formation, J Bone Min Res 19 (S1): M272, 2004.
Kostenuik PJ, Stolina M, Bolon B, Adamu S, Asuncion F, Morony S, Schett G, Middleton S, Feige U, Zack D, RANKL and TRAP-5b are markers of bone destruction in two rat models of inflammatory arthritis, J Bone Min Res 19 (S1): SA510, 2004.
Kostenuik PJ, Asuncion F, Warmington K, Morony S, Tan H, Grinsanti M, Adamu S, Coupling of bone resorption and bone formation: A comparison of a RANKL antagonist (OPG) and bisphosphanates in mice, J Bone Min Res 19 (S1): M300, 2004.
Milani JK, Verbukh I, Pleyer U, Sumner H, Adamu SA, Pitchekian-Halabi H, Chou HJ, Lee DA, Mondino BJ. Collagen shields impregnated with a gentamicin-dexamethasone combination as a potential drug delivery device after intraocular surgery. Invest. Ophthalmol. Vis. Sci. (ARVO supp.) 855, 1993.
Mondino BJ, Giese MJ, Sumner H, Adamu SA, Pitchekian-Halabi H, Chou HJ. The complement system and host defense against Staphylococcus aureus endophthalmitis. Invest. Ophthalmol. Vis. Sci. (ARVO supp.) 1258, 1993.
Giese MJ, Mondino BJ, Sumner H, Adamu SA, Pitchekian-Halabi H, Chou HJ. The complement system and host defense against Staphylococcus epidermidis endophthalmitis. Invest. Ophthalmol. Vis. Sci. (ARVO supp.) 919, 1993.
Engstrom RE, Mondino BJ, Pitchekian-Halabi H, Adamu SA. Immune response in Staphylococcus aureus endophthalmitis. Invest. Ophthalmol. Vis. Sci. 31 (ARVO supp.) 450, 1990.
Gascon R, Adamu SA, Bermudez L, Lancero M, Young LS, 1985. Functional activity of monoclonal antibody against common core lipopolysaccharide antigen of P. aeruginosa. 24th Interscience Conference of Antimicrobial Agents and Chemotherapy. Minnesota, September 1985.
Hong D, Adamu SA, Stevens P, 1984. Monoclonal antibodies to a protein of Candida albicans. 23rd Interscience Conference of Antimicrobial Agents and Chemotherapy. Washington D.C., October 1984.
Adamu SA, Stevens P, Young LS, 1982. E. coli K5 capsular antigen prevalence and mechanism of resistance to phagocytosis. 22nd Interscience Conference of Antimicrobial Agents and Chemotherapy. Miami, Fla., October 1982.Stevens P, Young LS,
Adamu SA, 1981. Serum Opsonic requirements for various capsular (K) serotypes of E. coli. 21st Interscience conference on Antimicrobial Agents and Chemotherapy. Chicago, III. November 1981.